(Q33406835)

26 July 2017

title

Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review (English)

1 reference

26 July 2017

0 references

1 reference

1 reference

1 reference

Roxana Sirli

3

0 references

author name string

Simona Bota

1

1 reference

26 July 2017

Ioan Sporea

2

1 reference

26 July 2017

Alina Popescu

4

1 reference

26 July 2017

Adriana Maria Neghină

5

1 reference

26 July 2017

Mirela Dănilă

6

1 reference

26 July 2017

Mihnea Străin

7

1 reference

26 July 2017

publication date

1 March 2013

1 reference

World Journal of Hepatology

26 July 2017

published in

1 reference

26 July 2017

volume

5

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

120-126

1 reference

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Response to standard of care antiviral treatment in patients with HCV liver cirrhosis - a systematic review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Telaprevir for retreatment of HCV infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Boceprevir for previously treated chronic HCV genotype 1 infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Boceprevir for untreated chronic HCV genotype 1 infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

A review of the treatment of chronic hepatitis C virus infection in cirrhosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Telaprevir for previously treated chronic HCV infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Treatment of chronic hepatitis C virus infection with pegylated interferon and ribavirin in cirrhotic patients awaiting liver transplantation.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Epidemiology of hepatitis C virus infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Effectiveness of pegylated interferon and ribavirin in patients with liver HCV cirrhosis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Diagnosis, management, and treatment of hepatitis C

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Treatment of patients with hepatitis C and cirrhosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis.

21 June 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I3.120

Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I3.120

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I3.120

Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I3.120

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I3.120

Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I3.120

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I3.120

Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I3.120

Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I3.120

Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I3.120

Sustained virological response to pegylated interferon and ribavirin in patients with genotype 3 HCV cirrhosis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612570

Natural history of hepatitis C

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23556044

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4254/WJH.V5.I3.120

1 reference

26 July 2017

1 reference

26 July 2017

1 reference